For a better experience, Read this story in our App
TO ENJOY ADDITIONAL BENEFITS
Connect With Us
Get BusinessLine apps on
The European Commission has withdrawn the marketing authorisation to AstraZeneca’s Covid-19 vaccine Vaxzevria, on the company’s request.
The Commission’s decision comes into effect today (May 7th)). An application to withdraw was made by AstraZeneca on March 5th 2024.
“Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic. As multiple, variants of Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzervria, which is no longer being manufactured or supplied,” AstraZeneca said in its statement to queries from businessline.
The company is currently facing a class action suit in the UK, from a small number of families affected by the vaccine, media reports from the UK said. The company is reported to have said in Court documents (in February) that the vaccine could “in very rare cases, cause TTS” (thrombosis with thrombocytopenia syndrome – blood clots and low platelet counts), according to reports.
AstraZeneca’s vaccine was produced and sold in India through an alliance with Serum Institute of India, under the brand name Covishield. Over 170 crore doses of this vaccine were given in India. The company did not comment on the UK development, since the case was in Court.
Meanwhile, Indian families where a member allegedly countered an adverse effect from the vaccine or died, are also preparing to take the legal recourse.
A person familiar with the development said, the application to withdraw was not due to safety issues.
AstraZeneca’s statement said, “We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally.” Further, it added, that they would work with regulators and partners “to align on a clear path forward to conclude this chapter.”
Published on May 7, 2024
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.